Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000267800 corresponds to a **pseudogene** of the SMT3 suppressor of mif two 3 homolog 2 (SUMO2) gene rather than to a functional protein-coding gene or direct therapeutic target[4]. Pseudogenes are non-functional genomic DNA sequences similar to known genes but typically do not produce active proteins. The true gene, SUMO2 (small ubiquitin-like modifier 2), is a member of the SUMO protein family involved in post-translational modification of other proteins and diverse cellular processes such as nuclear transport and regulation of transcription[1][3][6]. However, as a pseudogene, ENSG00000267800 does not encode a functional protein and has no established therapeutic, biological, or disease role. **Clarification:** There is a functional gene, **SUMO2** (small ubiquitin-like modifier 2), which is often studied for its cellular and disease relevance, but ENSG00000267800 specifically refers to a **pseudogene** version, which is not an active drug target[4]. If you seek information on the active SUMO2 protein, use the entry ENSG00000188612 instead[3]. **Summary of issues:** - ENSG00000267800 is a pseudogene and not a functional molecule of therapeutic interest[4]. - It is not considered a valid drug target, nor does it have known protein, disease, or drug associations. - Any search for functional data should use the canonical SUMO2 gene rather than its pseudogene counterpart.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SMT3 suppressor of mif two 3 homolog 2, pseudogene.